Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philippe Moreau

Showing results (51-60 of 787) with videos related to

Pageof 79
Sort By:
Expert Review of Hematology|January 24, 2017
Triplet combinations in relapsed/refractory myeloma: update on recent phase 3 trialsJean-Samuel Boudreault, Cyrille Touzeau, Philippe Moreau
Critical Reviews in Oncology/Hematology|March 23, 2017
How have evolutions in strategies for the treatment of relapsed/refractory multiple myeloma translated into improved outcomes for patients?Pieter Sonneveld, Edwin De Wit, Philippe Moreau
Journal of Cellular and Molecular Medicine|June 11, 2009
Non-classical transcriptional regulation of HLA-G: an updatePhilippe Moreau, Sébastien Flajollet, Edgardo D Carosella
Blood Cancer Journal|March 22, 2019
Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomidePhilippe Moreau, Elena Zamagni, Maria-Victoria Mateos
Expert Opinion on Investigational Drugs|July 13, 2021
Immune checkpoint inhibitors for the treatment of myeloma: novel investigational optionsBaptiste Le Calvez, Philippe Moreau, Cyrille Touzeau
British Journal of Haematology|September 20, 2014
Bortezomib-thalidomide-dexamethasone versus bortezomib-cyclophosphamide-dexamethasone as induction therapy prior to autologous stem cell transplantation in multiple myelomaPhilippe Moreau, Jean-Yves Mary, Michel Attal
The New England Journal of Medicine|June 30, 2007
Allografting or autografting for myelomaPhilippe Moreau, Jean-Luc Harousseau, Michel Attal
The New England Journal of Medicine|November 2, 2022
Teclistamab in Relapsed or Refractory Multiple Myeloma. ReplyPhilippe Moreau, Suzette Girgis, Jenna D Goldberg
Optics Express|August 10, 2017
Optimizing the metric in sensorless adaptive optical microscopy with fluorescence fluctuationsJoseph Gallagher, Antoine Delon, Philippe Moreau, et al.
Advances in Therapy|September 29, 2016
The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European PerspectiveJesus F San-Miguel, Hermann Einsele, Philippe Moreau
Pageof 79

Showing results (51-60 of 787) with videos related to

Sort By:
Pageof 79
Expert Review of Hematology|January 24, 2017
Triplet combinations in relapsed/refractory myeloma: update on recent phase 3 trialsJean-Samuel Boudreault, Cyrille Touzeau, Philippe Moreau
Critical Reviews in Oncology/Hematology|March 23, 2017
How have evolutions in strategies for the treatment of relapsed/refractory multiple myeloma translated into improved outcomes for patients?Pieter Sonneveld, Edwin De Wit, Philippe Moreau
Journal of Cellular and Molecular Medicine|June 11, 2009
Non-classical transcriptional regulation of HLA-G: an updatePhilippe Moreau, Sébastien Flajollet, Edgardo D Carosella
Blood Cancer Journal|March 22, 2019
Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomidePhilippe Moreau, Elena Zamagni, Maria-Victoria Mateos
Expert Opinion on Investigational Drugs|July 13, 2021
Immune checkpoint inhibitors for the treatment of myeloma: novel investigational optionsBaptiste Le Calvez, Philippe Moreau, Cyrille Touzeau
British Journal of Haematology|September 20, 2014
Bortezomib-thalidomide-dexamethasone versus bortezomib-cyclophosphamide-dexamethasone as induction therapy prior to autologous stem cell transplantation in multiple myelomaPhilippe Moreau, Jean-Yves Mary, Michel Attal
The New England Journal of Medicine|June 30, 2007
Allografting or autografting for myelomaPhilippe Moreau, Jean-Luc Harousseau, Michel Attal
The New England Journal of Medicine|November 2, 2022
Teclistamab in Relapsed or Refractory Multiple Myeloma. ReplyPhilippe Moreau, Suzette Girgis, Jenna D Goldberg
Optics Express|August 10, 2017
Optimizing the metric in sensorless adaptive optical microscopy with fluorescence fluctuationsJoseph Gallagher, Antoine Delon, Philippe Moreau, et al.
Advances in Therapy|September 29, 2016
The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European PerspectiveJesus F San-Miguel, Hermann Einsele, Philippe Moreau
Pageof 79